-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Japanese Dividend Stocks To Own In September 2026

Simply Wall St·09/06/2026 09:25:43
Listen to the news

Japan’s yield moves and Bank of Japan policy debates keep investors focused on income as interest rate expectations evolve. That puts reliable dividend payers with 3%+ yields in the spotlight for anyone who wants regular cash flow from Japanese dividend stocks rather than relying only on price swings. This article walks through three high yielding companies from a quality screen and explains what makes their dividends look relatively dependable.

The three stocks covered next are just a small sample of this dividend income idea. The full screen on Simply Wall St surfaces 461 more companies with similarly appealing yield profiles and business stories that are not covered here.

If you want to identify and analyze a broader set of high yield opportunities with strong coverage and stability, head straight into the Dividend Powerhouses (3%+ Yield) screener.

Tokio Marine Holdings (TSE:8766)

Tokio Marine Holdings is a large Japanese insurer that provides a wide range of property, casualty and life insurance products, along with reinsurance, asset management and various risk and solution services. Its dividend appeal is closely tied to the recurring cash flows from domestic property and casualty insurance, which generated about ¥3,163b in revenue, and domestic life insurance at roughly ¥445b, complemented by around ¥5,408b from overseas insurance and ¥328b from solution and other business. The company has a market cap of about ¥15,154b, which puts it among the larger listed insurers in Japan.

Tokio Marine Holdings gives you exposure to a global insurance group that pairs income appeal with ongoing change behind the scenes. Core property, casualty and life insurance cash flows help support a 3.07% dividend yield, while recent results and share buybacks point to active capital returns. At the same time, the business is working through margin pressure, funding risks and a shift away from less profitable equity holdings and past practices in Japan. For anyone focused on reliable dividends, the key issue is how these moving parts affect dividend resilience over the next few years, and whether recent earnings and valuation signals are sufficient to justify a closer look.

Tokio Marine Holdings is reshaping its global insurance mix while feeding a 3.07% yield from sizeable domestic and overseas cash flows, yet the real story sits in how sustainable that income stream looks once you factor in margins, funding risks and capital returns in the 3 key rewards and 1 important warning sign

TSE:8766 Revenue & Expenses Breakdown as at Sep 2026
TSE:8766 Revenue & Expenses Breakdown as at Sep 2026

Daiichi Sankyo Company (TSE:4568)

Daiichi Sankyo Company is a global pharmaceutical group focused on oncology drugs such as Enhertu and Datroway, as well as cardiovascular treatments like Lixiana and Savaysa. Together, these help create the stable, cash-generating profile that supports its role in a Dividend Powerhouses screen. The business currently reports essentially all of its ¥2,223.2b revenue from its Pharmaceutical Operation segment. With a market cap of about ¥5,086.1b, Daiichi Sankyo Company sits among Japan’s larger listed pharma companies.

Income focused investors may find Daiichi Sankyo Company interesting because its dividend story is tied to blockbuster cancer and cardiovascular drugs that already have approvals, growing label expansions and fresh data, such as recent Enhertu and Datroway trial results through mid 2026 and the MILOS study in cholesterol management. At the same time, the 3.58% yield is not well covered by free cash flow and profit margins have softened. The key question is whether new indications, global partnerships and a deep antibody drug conjugate pipeline can support both future growth and a dividend that remains dependable rather than stretched.

Daiichi Sankyo Company is riding blockbuster oncology and cardiovascular drugs, yet its 3.58% yield sits on softer margins and thin free cash flow cover. Step into the 2 key rewards and 2 important warning signs (1 is major!) and see what these cross currents might really mean for the dividend story.

TSE:4568 Revenue & Expenses Breakdown as at Sep 2026
TSE:4568 Revenue & Expenses Breakdown as at Sep 2026

Japan Tobacco (TSE:2914)

Japan Tobacco is a global tobacco group that manufactures cigarettes, cigars, heated and vapor reduced risk products, as well as a smaller processed food business. The Tobacco segment is the key link to the Dividend Powerhouses theme, generating about ¥3,602.2b in revenue and funding the company’s high dividend profile. Processed foods contribute around ¥162.0b alongside a small amount from other activities. With a market cap of roughly ¥12,078.3b, Japan Tobacco is one of the larger listed consumer companies in Japan.

Income focused investors may want Japan Tobacco on their radar because its high margin tobacco portfolio, from Winston and Camel to heated products, has been throwing off strong earnings and supporting regular dividend increases, including a higher 2026 payout. At the same time, the current yield is closer to 4% and free cash flow coverage is thin, so the dividend story depends on continued profit strength and careful investment in still unprofitable reduced risk products. In addition, the stock trades at a premium P/E, faces mixed governance signals and relies on funding that leans on higher risk liabilities. As a result, the income appeal is clear but the full balance between reward and risk needs a closer look.

Japan Tobacco’s rich yield and premium P/E suggest that the market may be pricing in more than just steady cigarettes and heated products. The real twist sits inside the 3 key rewards and 1 important warning sign

TSE:2914 P/E Ratio as at Sep 2026
TSE:2914 P/E Ratio as at Sep 2026

Seeking Alternatives Before The Crowd?

Fresh dividend ideas do not stay quiet for long. Once momentum hits, prices can move fast and entry points can quickly move out of reach. Review these screens and consider your options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.